1. Medtech Insight
  2. >>Business

Boston Scientific Exceeds Wall Street’s Expectations In Q3

 
• By Reed Miller

Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.

Sep 16, 2019 Fremont / CA / USA - Boston Scientific office buildings in Silicon Valley; Boston Scientific Corporation is a manufacturer of medical devices used in interventional medical specialties
• Source: shutterstock.com

Boston Scientific’s third-quarter 2020 revenue total is higher than Wall Street analysts expected it to be, but it is still lower than it was a year ago due to the slowdown in procedures caused by the pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 
• By Natasha Barrow

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Birmingham City University Develops New Defense Mechanism Against Cyberattacks On AI Systems

 
• By Natasha Barrow

AI systems used in healthcare are vulnerable to adversarial cyberattacks, which are a growing concern, said Atif Azad, a professor of AI at Birmingham City University. Azad’s research group has developed a method that trains AI to become more resilient to cyber threats through the use of random image adjustments.

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By Marion Webb

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

More from Medtech Insight

OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

 
• By Shubham Singh

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single-cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

Secretary Kennedy’s FDA Visit Included CDRH Stop, Speech Warning Of ‘Agency Capture’

 
• By Sue Sutter

HHS Secretary Robert F. Kennedy Jr. urged FDA staff to resist the “deep state” and “crony capitalism,” and focus on improving the health of America’s children. “You're not here to take orders,” he said and urged FDA staff to speak up if they see wrongdoing.

Execs On The Move: 31 March to 4 April 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.